Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 21;12(10):1670.
doi: 10.3390/life12101670.

Atopic Dermatitis with Multiple Comorbidities Treated with Dupilumab. A Case Report and Review of the Literature Regarding the Safety of Dupilumab

George G Mitroi  1 , Loredana Elena Stoica  1 , George F Mitroi  2 , Mihaela Roxana Mitroi  3 , Cristina Violeta Tutunaru  1 , Oana Maria Ică  1 , Laura Simona Ianoși  1
Affiliations
Review

Atopic Dermatitis with Multiple Comorbidities Treated with Dupilumab. A Case Report and Review of the Literature Regarding the Safety of Dupilumab

George G Mitroi et al. Life (Basel). .

Abstract

Dupilumab is the only available biological treatment for moderate-to-severe atopic dermatitis (AD). Even so, limited clinical data regarding its safety profile are available. Interactions with other drugs and the adverse effects of Dupilumab on patients with multiple comorbidities, such as chronic heart disease, diabetes, chronic kidney disease, etc., are not known yet. Moreover, there have been described cases of cutaneous lymphomas induced by Dupilumab. Therefore, the clinician that wants to start treatment for moderate-to-severe atopic dermatitis, which does not respond to conventional drugs, might be reluctant to choose biologic agents such as Dupilumab. In this paper, we reported a case of severe atopic dermatitis with multiple comorbidities in which the patient was successfully treated with Dupilumab despite numerous underlying conditions. We also conducted a review of the current literature on the safety profile of Dupilumab in special categories of patients with comorbidities, such as heart, kidney, and liver disease, oncologic conditions, and during pregnancy.

Keywords: Dupilumab; atopic dermatitis; cancer; comorbidities; pregnancy; safety.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Post-grating excoriations, xerosis, hematic crusts visible on the skin.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Nutten S. Atopic dermatitis: Global epidemiology and risk factors. Ann. Nutr. Metab. 2015;66((Suppl. 1)):8–16. doi: 10.1159/000370220. - DOI - PubMed
    1. Brunner P.M., Guttman-Yassky E., Leung D.Y. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J. Allergy Clin. Immunol. 2017;139:S65–S76. doi: 10.1016/j.jaci.2017.01.011. - DOI - PMC - PubMed
    1. Kader H.A., Azeem M., Jwayed S.A., Al-Shehhi A., Tabassum A., Ayoub M.A., Hetta H.F., Waheed Y., Iratni R., Al-Dhaheri A., et al. Current Insights into Immunology and Novel Therapeutics of Atopic Dermatitis. Cells. 2021;10:1392. doi: 10.3390/cells10061392. - DOI - PMC - PubMed
    1. Villani A.P., Pavel A.B., Wu J., Fernandes M., Maari C., Saint-Cyr Proulx E., Jack C., Glickman J., Choi S., He H., et al. Vascular inflammation in moderate-to-severe atopic dermatitis is associated with enhanced Th2 response. Allergy. 2021;76:3107–3121. doi: 10.1111/all.14859. - DOI - PubMed
    1. Adachi S., Oshikata C., Kaneko T., Tsurikisawa N. Rituximab and dupilumab improve eosinophilic granulomatosis with polyangiitis with multiple pulmonary thrombi. Allergy Asthma Clin. Immunol. 2022;18:18. doi: 10.1186/s13223-021-00639-x. - DOI - PMC - PubMed

LinkOut - more resources